🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementSulfur burps on tirzepatide — mechanism and solutions

Sulfur burps on tirzepatide — mechanism and solutions

Dr.GutHealth Mon, Jun 1, 2026 at 7:28 PM 4 replies 234 viewsPage 1 of 1
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 1, 2026 at 7:28 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

Marking this solved because it was, and putting the answer at the top so nobody has to read nine replies to find it.

What it turned out to be: Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

The question I want answered is what distinguishes the nausea you can titrate through from the nausea that means stop. Tell me what I have not thought of.

50 20VanRx_Mike, steve_okc, dave_SLC and 47 others
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Jun 1, 2026 at 7:47 PM#2

This one has a reasonably settled answer, so here it is. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Jun 2, 2026 at 1:47 AM
49 19JenPlateau, SallyK_inj, CryptoCarl and 46 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Jun 1, 2026 at 8:06 PM#3
HPLC_Greg said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

48 18AttorneyGrant, DebRD_ATL, KristenIndy and 45 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
Jun 1, 2026 at 8:25 PM#4
Dr.GutHealth said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

This matches mine closely enough to be worth saying so. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: Jun 2, 2026 at 1:25 AM
47 17KetoKyle, CanadaChris, ZaraB_AL and 44 others
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Jun 1, 2026 at 10:10 PM#5

From the other side of the consultation, briefly. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

46 16mike_mealprep, NicoleRaleigh, james_edin and 43 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register